摘要
目的探究微小RNA-218(miR-218)、miR-21在幽门螺旋杆菌(Helicobacter pylori,Hp)感染相关胃癌组织中的表达及临床意义。方法选取接受手术切除的胃癌患者104例,分析miR-218和miR-21表达与Hp感染胃癌患者临床病理因素及术后复发的关系。结果Hp阳性组患者胃癌组织中miR-218水平低于Hp阴性组,miR-21水平、2年复发率高于Hp阴性组(P均<0.05);Hp感染胃癌患者胃癌组织中miR-218水平低于癌旁组织,miR-21水平高于癌旁组织(P均<0.05);miR-218和miR-21表达与患者分化程度、TNM分期、肿瘤浸润深度、淋巴结转移及无疾病进展生存率相关,对术后2年复发情况具有较高的预测价值。结论miR-218和miR-21水平在Hp感染和无Hp感染的胃癌患者中存在差异表达,其异常表达与Hp感染胃癌患者临床病理因素及预后存在关联。
Objective To explore expressions of miRNA-218(miR-218)and miR-21 in gastric cancer related to Helicobacter pylori(Hp)infection and their clinical significance.Methods A total of 104 patients with gastric cancer undergoing surgical resection were enrolled.The relationship between miR-218,miR-21 and clinicopathological factors and postoperative recurrence was analyzed.Results The expression Level of miR-218 was lower in the Hp-positive group than in the Hp-negative group,while the expression level of miR-21 and the 2-year recurrence rate were higher in the Hp-positive group(P<0.05).The expression level of miR-218 was lower in the gastric cancer tissues than in the para-carcinoma tissues,while the expression level of miR-21 was higher in the gastric cancer tissues(P<0.05).The expression levels of miR-218 and miR-21 were correlated with the differentiation degree,TNM staging,depth of tumor invasion,lymph node metastasis and progression-free survival rate,which were of high predictive value for the 2-year recurrence situation after surgery.Conclusion The expression levels of miR-218 and miR-21 are different between gastric cancer patients with or without Hp-infection.The abnormal expressions of miR-218 and miR-21 are related with the clinicopathological factors and prognosis of gastric cancer patients with Hp infection.
作者
邹玲
张恒
吴剑
林伟
陈欣
ZOU Ling;ZHANG Heng;WU Jian;LIN Wei;CHEN Xin(Department of Gastroenterology,Panzhihua Group General Hospital,Panzhihua,Sichuan,617000,China;Department of General Surgery,Panzhihua Group General Hospital,Panzhihua,Sichuan,617000,China)
出处
《医学分子生物学杂志》
CAS
2024年第3期259-263,共5页
Journal of Medical Molecular Biology
基金
攀钢集团总医院科技研发项目,四川省科技计划项目(No.2022-JYJ-59)。